New hope for women with resistant ovarian cancer
NCT ID NCT06856499
Summary
This early-stage study is testing whether combining two drugs, Cirtuvivint and Olaparib, is safe and tolerable for women with a specific type of ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The trial will enroll about 50 women who have already tried a PARP inhibitor drug. The main goals are to find the safest dose of the combination and understand how the body processes the new drug, Cirtuvivint.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CU Medicine Clinics
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universtiy of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.